Alvotech
A maker of biosimilar medicines, Alvotech develops lower-cost copies of expensive biologic drugs used to treat illnesses like arthritis and eye disease. Founded in 2013 in Reykjavík, Iceland, by serial pharma entrepreneur Róbert Wessman—the same man behind generics firm Alvogen—the company was built to handle every step from cell lines to manufacturing under one roof. Its name blends "Alvogen" with "tech," and in 2022 it became the first Icelandic firm listed on both a US and Icelandic stock exchange.
Item 4 is hereby amended and supplemented as follows: On June 26, 2026, Celtic Lux purchased aggregate of 10,133,333 Ordinary Shares, at a price of $3.75 per share, for an aggregate investment of $38,000,000 (such investment, the "PIPE Investment") pursuant to the terms of a subscription agreement (the "Subscription Agreement") dated June 16, 2026, by and between Celtic Lux and the Issuer. In connection with the PIPE Investment, pursuant to the Subscription Agreement, Celtic Lux was granted registration rights pursuant to which Celtic Lux may, at any time and from time to time, make a written demand for registration under the Securities Act of 1933, as amended, of all or any portion of the shares purchased by it in the PIPE Investment on any available form of registration statement (a "Demand Registration"), including by way of an underwritten offering with underwriters selected by Celtic Lux and reasonably acceptable to the Issuer. The Issuer is obligated, using its reasonable best efforts and as expeditiously as possible after receipt of such demand, to prepare and file with the SEC a registration statement covering the resale of such shares and to keep such registration statement effective until all such shares have been disposed of or withdrawn. The Issuer is not obligated to effect more than two (2) Demand Registrations in total. The Issuer has the right to defer any Demand Registration for up to 60 days in total, or 30 consecutive days, in any 12-month period if the Issuer's board of directors determines in good faith that effecting the registration at that time would be materially detrimental to the Issuer and its shareholders. All costs and expenses incurred in connection with a Demand Registration are to be borne by the Issuer. The Issuer also agreed to provide customary indemnification to Celtic Lux in connection with its registration rights. The foregoing description of the PIPE Investment is qualified in its entirety by reference to the Subscription Agreement, which is filed as Exhibit 9 to this Amendment.
Item 4 is hereby amended and supplemented as follows: On June 26, 2026, Celtic Lux purchased aggregate of 10,133,333 Ordinary Shares, at a price of $3.75 per share, for an aggregate investment of $38,000,000 (such investment, the "PIPE Investment") pursuant to the terms of a subscription agreement (the "Subscription Agreement") dated June 16, 2026, by and between Celtic Lux and the Issuer. In connection with the PIPE Investment, pursuant to the Subscription Agreement, Celtic Lux was granted registration rights pursuant to which Celtic Lux may, at any time and from time to time, make a written demand for registration under the Securities Act of 1933, as amended, of all or any portion of the shares purchased by it in the PIPE Investment on any available form of registration statement (a "Demand Registration"), including by way of an underwritten offering with underwriters selected by Celtic Lux and reasonably acceptable to the Issuer. The Issuer is obligated, using its reasonable best efforts and as expeditiously as possible after receipt of such demand, to prepare and file with the SEC a registration statement covering the resale of such shares and to keep such registration statement effective until all such shares have been disposed of or withdrawn. The Issuer is not obligated to effect more than two (2) Demand Registrations in total. The Issuer has the right to defer any Demand Registration for up to 60 days in total, or 30 consecutive days, in any 12-month period if the Issuer's board of directors determines in good faith that effecting the registration at that time would be materially detrimental to the Issuer and its shareholders. All costs and expenses incurred in connection with a Demand Registration are to be borne by the Issuer. The Issuer also agreed to provide customary indemnification to Celtic Lux in connection with its registration rights. The foregoing description of the PIPE Investment is qualified in its entirety by reference to the Subscription Agreement, which is filed as Exhibit 9 to this Amendment.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Celtic Holdings S.C.A. | 13D/AActivist | 27.5% | 107.45M | Jun 30, 2026 |
Item 4 is hereby amended and supplemented as follows: On June 26, 2026, Celtic Lux purchased aggregate of 10,133,333 Ordinary Shares, at a price of $3.75 per share, for an aggregate investment of $38,000,000 (such investment, the "PIPE Investment") pursuant to the terms of a subscription agreement (the "Subscription Agreement") dated June 16, 2026, by and between Celtic Lux and the Issuer. In connection with the PIPE Investment, pursuant to the Subscription Agreement, Celtic Lux was granted registration rights pursuant to which Celtic Lux may, at any time and from time to time, make a written demand for registration under the Securities Act of 1933, as amended, of all or any portion of the shares purchased by it in the PIPE Investment on any available form of registration statement (a "Demand Registration"), including by way of an underwritten offering with underwriters selected by Celtic Lux and reasonably acceptable to the Issuer. The Issuer is obligated, using its reasonable best efforts and as expeditiously as possible after receipt of such demand, to prepare and file with the SEC a registration statement covering the resale of such shares and to keep such registration statement effective until all such shares have been disposed of or withdrawn. The Issuer is not obligated to effect more than two (2) Demand Registrations in total. The Issuer has the right to defer any Demand Registration for up to 60 days in total, or 30 consecutive days, in any 12-month period if the Issuer's board of directors determines in good faith that effecting the registration at that time would be materially detrimental to the Issuer and its shareholders. All costs and expenses incurred in connection with a Demand Registration are to be borne by the Issuer. The Issuer also agreed to provide customary indemnification to Celtic Lux in connection with its registration rights. The foregoing description of the PIPE Investment is qualified in its entirety by reference to the Subscription Agreement, which is filed as Exhibit 9 to this Amendment. | ||||
| Celtic Lux Holdings S.a r.l. | 13D/AActivist | 27.5% | 107.45M | Jun 30, 2026 |
Item 4 is hereby amended and supplemented as follows: On June 26, 2026, Celtic Lux purchased aggregate of 10,133,333 Ordinary Shares, at a price of $3.75 per share, for an aggregate investment of $38,000,000 (such investment, the "PIPE Investment") pursuant to the terms of a subscription agreement (the "Subscription Agreement") dated June 16, 2026, by and between Celtic Lux and the Issuer. In connection with the PIPE Investment, pursuant to the Subscription Agreement, Celtic Lux was granted registration rights pursuant to which Celtic Lux may, at any time and from time to time, make a written demand for registration under the Securities Act of 1933, as amended, of all or any portion of the shares purchased by it in the PIPE Investment on any available form of registration statement (a "Demand Registration"), including by way of an underwritten offering with underwriters selected by Celtic Lux and reasonably acceptable to the Issuer. The Issuer is obligated, using its reasonable best efforts and as expeditiously as possible after receipt of such demand, to prepare and file with the SEC a registration statement covering the resale of such shares and to keep such registration statement effective until all such shares have been disposed of or withdrawn. The Issuer is not obligated to effect more than two (2) Demand Registrations in total. The Issuer has the right to defer any Demand Registration for up to 60 days in total, or 30 consecutive days, in any 12-month period if the Issuer's board of directors determines in good faith that effecting the registration at that time would be materially detrimental to the Issuer and its shareholders. All costs and expenses incurred in connection with a Demand Registration are to be borne by the Issuer. The Issuer also agreed to provide customary indemnification to Celtic Lux in connection with its registration rights. The foregoing description of the PIPE Investment is qualified in its entirety by reference to the Subscription Agreement, which is filed as Exhibit 9 to this Amendment. | ||||
| Aztiq Pharma Partners S.a r.l. | 13D/AActivist | 33.3% | 103.85M | Mar 12, 2026 |
| Aztiq Fund I SCSp | 13D/AActivist | 33.3% | 103.85M | Mar 12, 2026 |
| Floki GP S.a r.l. | 13D/AActivist | 33.3% | 103.85M | Mar 12, 2026 |
| ATP ehf. | 13D/AActivist | 1% | 3.00M | Mar 12, 2026 |
| ATP Holdings ehf. | 13D/AActivist | 1% | 3.02M | Mar 12, 2026 |